Cadence Pharmaceuticals Completes $49.3 Million Registered Direc...(would be unlawfulprior to the registrati...)

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections.

Forward-Looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the advancement of the company's clinical development programs for its product candidates, the timeframes in which the company expects to file submissions with regulatory authorities seeking marketing authorization for its product candidates, and the adequacy of the company's funding to advance its product candidates through to NDA submissions. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: Cadence's dependence on the success of its only two product candidates; delays in completing the company's clinical trials or achieving its product development goals, or significant issues regarding the results, design or execution of its clinical trials; the potential need to expand Cadence's ongoing clinical trials or to conduct additional clinical trials; the market potential for the company's product candidates, and its ability to compete with new or existing products; unanticipated adverse side effects or inadequate therapeutic efficacy of its product candidates; delays or quality issues
'/>"/>